Please Wait
Applying Filters...

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Leucid Bio is a clinical-stage biotechnology company pioneering next-generation cell therapies for hard-to-treat cancers, particularly solid tumors. Founded in 2014 to translate over 20 years of CAR-T research led by Dr. John Maher at King's College London, Leucid has developed a proprietary Lateral CAR platform. This platform redesigns CAR structures to mimic natural immune receptor configurations, enhancing T-cell potency an...
Leucid Bio is a clinical-stage biotechnology company pioneering next-generation cell therapies for hard-to-treat cancers, particularly solid tumors. Founded in 2014 to translate over 20 years of CAR-T research led by Dr. John Maher at King's College London, Leucid has developed a proprietary Lateral CAR platform. This platform redesigns CAR structures to mimic natural immune receptor configurations, enhancing T-cell potency and persistence while reducing toxicity.

List your booth number for exhibitions, ask us